Indolent Non-Hodgkin's Lymphomas Completed Phase 1 / 2 Trials for Idelalisib (DB09054)

Also known as: Indolent Non-Hodgkin Lymphoma / Indolent Non-Hodgkin's Lymphoma

IndicationStatusPhase
DBCOND0061053 (Indolent Non-Hodgkin's Lymphomas)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01306643Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade LymphomaTreatment